(Q39327140)

11 September 2017

title

Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy (English)

1 reference

non-small-cell lung carcinoma

11 September 2017

1 reference

1 reference

Lei Wang

1

1 reference

11 September 2017

Long Meng

2

1 reference

11 September 2017

Xing-wen Wang

3

1 reference

11 September 2017

Guo-yuan Ma

4

1 reference

11 September 2017

Jing-han Chen

5

1 reference

11 September 2017

publication date

24 October 2013

1 reference

11 September 2017

1 reference

11 September 2017

volume

35

1 reference

11 September 2017

issue

3

1 reference

11 September 2017

page(s)

1899-1906

1 reference

Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities' Consortium International Symposium, November 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

The let-7 microRNA represses cell proliferation pathways in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1255-4

Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line

21 January 2018

1 reference

12 December 2020

Overexpression of catalytic subunit M2 in patients with ovarian cancer.

1 reference

12 December 2020

Subunit M2 of mammalian ribonucleotide reductase. Characterization of a homogeneous protein isolated from M2-overproducing mouse cells.

1 reference

12 December 2020

[Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].

1 reference

12 December 2020

Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study

1 reference

12 December 2020

[The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer]

1 reference

12 December 2020

Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

12 December 2020

10.1007/S13277-013-1255-4

Identifiers

DOI

1 reference

11 September 2017

1 reference